title: Phase II study of mitomycin C plus 5-fluorouracil in patients with refractory ovarian cancer.
authors.forename: I
authors.initials: I
authors.lastname: Peláez
authors.forename: R
authors.initials: R
authors.lastname: López
authors.forename: I
authors.initials: I
authors.lastname: Palacio
authors.forename: Y
authors.initials: Y
authors.lastname: Fernández
authors.forename: E
authors.initials: E
authors.lastname: Estrada
authors.forename: E
authors.initials: E
authors.lastname: Esteban
authors.forename: J M
authors.initials: JM
authors.lastname: Buesa
authors.forename: A J
authors.initials: AJ
authors.lastname: Lacave
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage* / Q000009:adverse effects; D010051:Ovarian Neoplasms / Q000188:drug therapy*
chemical_list: D016685:Mitomycin; D005472:Fluorouracil